Author of

• 20163

  +

  P1.14 - Radiotherapy (ID 700)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22780

    +

    P1.14-013 - High Dose Radiotherapy (74Gy) Improved Local Progression Free Survival in Patients with Inoperable Stage III NSCLC (ID 8162)

    09:30 - 16:00  |  Presenting Author(s): Young Il Kim
    • Abstract

    Background:
    Local failure is common after concurrent or sequential chemo-radiation therapy for non-small cell lung cancer (NSCLC). Hypothesizing that a higher dose of radiation to the gross tumor volume (GTV) might increase local control of advanced NSCLC. We investigated whether high-dose radiation improved local control in patients with stage III NSCLC.
    
    Method:
    Sixty-four patients with stage III NSCLC were treated with three-dimensional conformal radiation therapy. Clinical target volume (CTV) contains GTV, plus a margin which is determined to consider the anatomic structure. Elective nodal irradiation had not been allowed. Patients with NSCLC were received high dose radiotherapy, 74Gy at CTV. The volume of lung receiving at least 20Gy (V20) is restricted to 25% because of lung toxicity. Acute and late toxicities were scored per the Common Terminology Criteria for Adverse Events version 4.0. The primary endpoint was overall survival (OS) and local progression free survival (LPFS) the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. All analyses were done by intention-to-treat.
    
    Result:
    Between Feb. 08, 2011 and Feb. 22, 2016, 64 patients received high dose radiotherapy and/or chemotherapy. 8 patients (12.5%) did not complete full dose radiotherapy. 3 patients stopped treatment voluntarily, 3 patients due to tumor progression during radiotherapy, and 2 patients dropped out of the treatment side effects – 1 neutropenia, 1 general weakness. Median follow-up was 14.6 months (1.2-51.6). Median OS was 20.0 months (1.2-65.6, and 3-year OS was 50.5%. Median LPFS was 15.7 months (1.2-57.0), and 3-year LPFS was 54.5%, retrospectively. Only one patient (1.6%) had grade 5 radiation induced pneumonitis. And other complication rates were tolerable which was compared with historical studies.
    
    Conclusion:
    High dose radiation is tolerable and contributes to improve outcomes, especially local progression free survival in patients with inoperable stage III non-small cell lung cancer, if radiation field is restricted to gross tumor only.